| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |